Drug Trial Radar · NCT05800977
A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
Last checked: Nov 20, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
112
Planned (sponsor's estimate)
Start
Feb 22, 2023
Primary completion
Mar 31, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Shanghai AbelZeta Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, single arm, open-label study. The purpose of the study is to evaluate safety of Prizloncabtagene Autoleucel (Prizlon-cel) and establish the recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the efficacy of Prizlon-cel (Phase 2) in patients with relapsed or refractory large b-cell lymphoma (LBCL).
Conditions
- Relapsed/Refractory Large B-Cell Lymphoma
Interventions
Prizloncabtagene autoleucelBiological
Prizlon-cel is a novel 2nd generation 4-1BB bispecific chimeric antigen receptor T-cell (CAR-T) targeting both CD19 and CD20 antigens
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b: Incidence and Severity of Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 90 days after C-CAR039 infusion
- Phase 1b: Recommended Phase 2 Dose (R2PD)Time frame: Up to 3 months after C-CAR039 infusion
- Phase 2: Overall Response Rate (ORR) at 3 monthsTime frame: Up to 3 months after C-CAR039 infusion
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, China · Completed
Beijing GoBroad Hospital
Beijing, China · Recruiting
Peking University Third Hospital
Beijing, China · Recruiting
Chongqing University Cancer Hospital
Chongqing, China · Recruiting
Guangdong Provincial People's Hospital
Guangzhou, China · Recruiting
Zhujiang Hospital of Southern Medical University
Guangzhou, China · Recruiting
The First Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, China · Recruiting
Cancer Hospital of Shandong First Medical University
Jinan, China · Recruiting
Jiangxi Cancer Hospital
Nanchang, China · Recruiting
Jiangsu Province Hospital
Nanjing, China · Recruiting
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China · Recruiting
Chinese Academy of Medical Sciences Hematology Hospital
Tianjin, China · Recruiting
Tianjin Medical University Cancer Institute& Hospital
Tianjin, China · Recruiting
Henan Cancer Hospital
Zhengzhou, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.